Clinical management of cognitive impairment in multiple sclerosis: a review of current evidence.
Over the past decade, there has been considerable interest in assessing the importance and functional impact of cognitive impairment in multiple sclerosis (MS), its clinico-magnetic resonance imaging correlates, and possible approaches to clinical management. There is preliminary evidence that treatment with both disease-modifying and symptomatic agents may positively influence the cognitive outcome of the patient, but few studies have assessed the efficacy of cognitive rehabilitation programmes using an experimental design. To make further progress in the field of neuropsychological diagnosis, it is essential to validate sensitive, cost-effective and reliable screening instruments that can be used, in clinical settings, to identify patients appropriate for extensive neuropsychological assessment, and finalize tailor-made rehabilitation techniques for MS patients.
Amato
M P
MP
Dipartimento Di Scienze, Neurologie e Psichiatriche, Universita di Firenze, USL 10/D, Vioale Morgagni 85, 50134 Florence, Italy. mariapia.amato@unifi.it
Zipoli
V
V
D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000145:classification / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000150:complications*; D009483:Neuropsychological Tests
D007166:Immunosuppressive Agents